| Project/Area Number |
23590175
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IKUMI Tamai 金沢大学, 薬学系, 教授 (20155237)
TAKEO Nakanishi 金沢大学, 薬学系, 准教授 (30541742)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 薬学 / 薬物動態学 / 経口吸収 / 徐放性製剤 / トランスポーター / 代謝酵素 / 薬物間相互作用 / 生体分子 |
|---|
| Research Abstract |
In the present study, we aimed to clarify the site-specific contribution of transporters and metabolic enzymes to the intestinal drug absorption. The rat in situ studies with talinolol and colchicine demonstrated site-specific drug absorption presumably due to differential expression and function of OATP and P-gp. Further analysis revealed presence of multiple binding sites on OATP2B1 with different affinity for drugs. Meanwhile, microsomal studies demonstrated that CYP3A5 genotype and expression level have a significant impact on inhibitory potency for CYP3A-catalyzed drug metabolism, but that the magnitude of its effect is inhibitor-substrate pair specific. The results of the study focusing on CYP2C19 show that, although metabolites contribute to in vivo DDIs, their relative abundance in circulation does not predict their contribution to in vivo DDI risk. These findings revealed involvement of influx/efflux transporters and metabolic enzymes in the intestinal drug absorption process.
|
